These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9267782)

  • 1. Prostate cancer: indicators of aggressiveness.
    Sakr WA; Grignon DJ
    Eur Urol; 1997; 32 Suppl 3():15-23. PubMed ID: 9267782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic markers in clinically localized prostate cancer.
    Pettaway CA
    Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.
    Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA
    Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
    Abaza R; Diaz LK; Laskin WB; Pins MR
    J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer.
    Lexander H; Palmberg C; Hellman U; Auer G; Hellström M; Franzén B; Jörnvall H; Egevad L
    Proteomics; 2006 Aug; 6(15):4370-80. PubMed ID: 16888723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
    Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
    J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deoxyribonucleic acid ploidy status as no basis for pathologic stage prediction in clinically resectable prostate cancer.
    Egawa S; Satoh T; Iwamura M; Aihara M; Kuwao S; Uchida T; Koshiba K
    Urology; 1996 Apr; 47(4):548-52. PubMed ID: 8638366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
    Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
    Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p27kip1 in prostatic adenocarcinoma.
    Cheville JC; Lloyd RV; Sebo TJ; Cheng L; Erickson L; Bostwick DG; Lohse CM; Wollan P
    Mod Pathol; 1998 Apr; 11(4):324-8. PubMed ID: 9578081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors that influence the measurement of prostate cancer DNA ploidy and proliferation in paraffin embedded tissue evaluated by flow cytometry.
    So MJ; Cheville JC; Katzmann JA; Riehle DL; Lohse CM; Pankratz VS; Sebo TJ
    Mod Pathol; 2001 Sep; 14(9):906-12. PubMed ID: 11557788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic characteristics of prostate cancer.
    Huncharek M; Muscat J
    Cancer Epidemiol Biomarkers Prev; 1995 Sep; 4(6):681-7. PubMed ID: 8547836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors.
    Bantis A; Gonidi M; Athanassiades P; Tsolos Ch; Liossi A; Aggelonidou E; Athanassiadou AM; Petrakakou E; Athanassiadou P
    J Exp Clin Cancer Res; 2005 Jun; 24(2):273-8. PubMed ID: 16110761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
    Cheng L; Koch MO; Juliar BE; Daggy JK; Foster RS; Bihrle R; Gardner TA
    J Clin Oncol; 2005 May; 23(13):2911-7. PubMed ID: 15860849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.
    Kauffman EC; Robinson VL; Stadler WM; Sokoloff MH; Rinker-Schaeffer CW
    J Urol; 2003 Mar; 169(3):1122-33. PubMed ID: 12576866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic dysplasia: significance in relation to nuclear DNA ploidy studies of prostate adenocarcinoma.
    Lieber MM
    Urology; 1989 Dec; 34(6 Suppl):43-8. PubMed ID: 2603285
    [No Abstract]   [Full Text] [Related]  

  • 19. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group.
    Grignon DJ; Hammond EH
    Arch Pathol Lab Med; 1995 Dec; 119(12):1122-6. PubMed ID: 7503660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MXI1 tumor suppressor gene is not mutated in primary prostate cancer.
    Kuczyk MA; Serth J; Bokemeyer C; Schwede J; Herrmann R; Machtens S; Grünewald V; Höfner K; Jonas U
    Oncol Rep; 1998; 5(1):213-6. PubMed ID: 9458379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.